Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome

Blood

Volumn 115, Issue 14, 2010, Pages 2928-2937

  Alford, Kate A ^a   Slender, Amy ^a   Vanes, Lesley ^a   Li, Zhe ^b   Fisher, Elizabeth M C ^c   Nizetic, Dean ^d   Orkin, Stuart H ^b   Roberts, Irene ^e   Tybulewicz, Victor L J ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; DOWN SYNDROME; GENE EXPRESSION; HEMATOPOIESIS; LEUKEMIA; MACROCYTIC ANEMIA; MEGAKARYOPOIESIS; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLENOMEGALY; TC1 STRAIN; TRISOMY 21;

EID: 77951074754     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-227629     Document Type: Article

References (35)

1. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004;5(10):725-738. (Pubitemid 39336357)
2. Henry E, Walker D, Wiedmeier SE, Christensen RD. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A. 2007;143(1):42-50. (Pubitemid 46051470)
3. Hord JD, Gay JC, Whitlock JA. Thrombocytopenia in neonates with trisomy 21. Arch Pediatr Adolesc Med. 1995;149(7):824-825.
4. Miller M, Cosgriff JM. Hematological abnormalities in newborn infants with Down syndrome. Am J Med Genet. 1983;16(2):173-177. (Pubitemid 14226093)
5. Roizen NJ, Amarose AP. Hematologic abnormalities in children with Down syndrome. Am J Med Genet. 1993;46(5):510-512. (Pubitemid 23172728)
6. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110(3):512-524.
7. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15(4):392-399. (Pubitemid 23320137)
8. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009;113(12):2619-2628.
9. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet. 2003;361(9369):1617-1620. (Pubitemid 36579001)
10. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101(11):4301-4304. (Pubitemid 36857793)
11. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101(11):4298-4300. (Pubitemid 36857792)
12. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986. (Pubitemid 36917793)
13. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-152. (Pubitemid 34977210)
14. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102(8):2960-2968. (Pubitemid 37248871)
15. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103(7):2480-2489. (Pubitemid 38392997)
16. Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112(12):4503-4506.
17. Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood. 2008;112(12):4507-4511.
18. De Vita S, Devoy A, Groet J, Kruslin B, Kuzmic-Prusac I, Nizetic D. Megakaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalis. Br J Haematol. 2008;143(2):300-303.
19. Migliaccio AR, Rana RA, Vannucchi AM, Manzoli FA. Role of GATA-1 in normal and neoplastic hemopoiesis. Ann N Y Acad Sci. 2005;1044:142-158.
20. Hollanda LM, Lima CS, Cunha AF, et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006;38(7):807-812.
21. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37(6):613-619. (Pubitemid 40770416)
22. Izraeli S, Rainis L, Hertzberg L, Smooha G, Birger Y. Trisomy of chromosome 21 in leukemogenesis. Blood Cells Mol Dis. 2007;39(2):156-159.
23. Davisson MT, Schmidt C, Akeson EC. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res. 1990;360:263-280.
24. Gardiner K, Fortna A, Bechtel L, Davisson MT. Mouse models of Down syndrome: how useful can they be? comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene. 2003;318:137-147. (Pubitemid 37338399)
25. Kirsammer G, Jilani S, Liu H, et al. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008;111(2):767-775.
26. Huang TT, Yasunami M, Carlson EJ, et al. Superoxide-mediated cytotoxicity in superoxide dismutase-deficient fetal fibroblasts. Arch Biochem Biophys. 1997;344(2):424-432. (Pubitemid 27344080)
27. Carmichael CL, Majewski IJ, Alexander WS, et al. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood. 2009;113(9):1929-1937.
28. O'Doherty A, Ruf S, Mulligan C, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science. 2005;309(5743):2033-2037. (Pubitemid 41362316)
29. Galante M, Jani H, Vanes L, et al. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum Mol Genet. 2009;18(8):1449-1463.
30. Morice E, Andreae LC, Cooke SF, et al. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn Mem. 2008;15(7):492-500. (Pubitemid 352008671)
31. Salek-Ardakani S, Smooha G, de Boer J, et al. ERG is a megakaryocytic oncogene. Cancer Res. 2009;69(11):4665-4673.
32. Stankiewicz MJ, Crispino JD. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood. 2009;113(14):3337-3347.
33. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101(11):4333-4341. (Pubitemid 36857797)
34. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008;205(3):585-594.
35. Bourquin JP, Subramanian A, Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006;103(9):3339-3344. (Pubitemid 43346471)